MA30720B1 - Analogues de 2-phenoxypyrimidinone - Google Patents
Analogues de 2-phenoxypyrimidinoneInfo
- Publication number
- MA30720B1 MA30720B1 MA31732A MA31732A MA30720B1 MA 30720 B1 MA30720 B1 MA 30720B1 MA 31732 A MA31732 A MA 31732A MA 31732 A MA31732 A MA 31732A MA 30720 B1 MA30720 B1 MA 30720B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenoxypyrimidinone
- ligands
- compounds
- analogues
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
L'INVENTION CONCERNE DES ANALOGUES DE LA 2-PHÉNOXYPYRIMIDINONE, DE FORMULE : DANS LAQUELLE LES VARIABLES SONT TELLES QUE DÉCRITES ICI. DE TELS COMPOSÉS SONT DES LIGANDS QUI PEUVENT ÊTRE UTILISÉS POUR MODULER L'ACTIVITÉ DE RÉCEPTEURS PARTICULIERS IN VIVO OU IN VITRO ET QUI SONT PARTICULIÈREMENT UTILES DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À L'ACTIVATION PATHOLOGIQUE DE RÉCEPTEURS CHEZ DES HUMAINS, DES ANIMAUX DE COMPAGNIE DOMESTIQUÉS ET LE BÉTAIL. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES ET DES PROCÉDÉS D'UTILISATION DE TELS COMPOSÉS POUR TRAITER DE TELS TROUBLES, AINSI QUE DES PROCÉDÉS D'UTILISATION DE TELS LIGANDS POUR DES ÉTUDES DE LOCALISATION DE RÉCEPTEURS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82325806P | 2006-08-23 | 2006-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30720B1 true MA30720B1 (fr) | 2009-09-01 |
Family
ID=39107411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31732A MA30720B1 (fr) | 2006-08-23 | 2009-03-23 | Analogues de 2-phenoxypyrimidinone |
Country Status (22)
Country | Link |
---|---|
US (2) | US8003656B2 (fr) |
EP (1) | EP2061794B1 (fr) |
JP (1) | JP5421108B2 (fr) |
KR (1) | KR20090043583A (fr) |
CN (2) | CN101506210A (fr) |
AU (1) | AU2007288203B2 (fr) |
BR (1) | BRPI0716582A2 (fr) |
CA (1) | CA2660957C (fr) |
CO (1) | CO6150167A2 (fr) |
CR (1) | CR10675A (fr) |
EA (1) | EA200900330A1 (fr) |
ES (1) | ES2399928T3 (fr) |
GT (1) | GT200900040A (fr) |
IL (1) | IL197043A0 (fr) |
MA (1) | MA30720B1 (fr) |
MX (1) | MX2009002066A (fr) |
NI (1) | NI200900023A (fr) |
NO (1) | NO20091182L (fr) |
SV (1) | SV2009003173A (fr) |
TW (1) | TW200825089A (fr) |
WO (1) | WO2008024438A2 (fr) |
ZA (1) | ZA200901163B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
AU2007288203B2 (en) | 2006-08-23 | 2013-01-17 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
EP3043784B9 (fr) | 2013-09-09 | 2019-11-20 | Peloton Therapeutics, Inc. | Aryléthers et utilisations de ceux-ci |
JP6667093B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC | ピリド[2,3−d]ピリミジン−2,4(1H,3H)−ジオン誘導体 |
EP3268362B1 (fr) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Pyridines substituées et leurs utilisations |
WO2016145032A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions utilisées pour traiter l'hypertension artérielle pulmonaire |
WO2016145045A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions s'utilisant dans le traitement du glioblastome |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
WO2016168510A1 (fr) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes |
WO2020146449A1 (fr) * | 2019-01-08 | 2020-07-16 | Texas Tech University System | Analogues de petites molécules de la protéine e4orf1 dans le traitement et la prévention de troubles métaboliques |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008113A1 (fr) * | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | COMPOSES DE 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE ET LEURS APPLICATIONS PHARMACOLOGIQUES |
US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
PT807633E (pt) * | 1996-05-15 | 2003-02-28 | Pfizer | Novas pirimidin-4-onas substituidas em 2,3, e fundidas com heteroarilo em (5,6) |
PL336581A1 (en) | 1997-05-08 | 2000-07-03 | Agrevo Uk Ltd | Fungicides |
US6627755B1 (en) * | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
US6323208B1 (en) * | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
AU2002214546A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
CA2433778A1 (fr) * | 2001-02-14 | 2002-08-22 | William Glen Harter | Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles |
EP1377576A2 (fr) | 2001-03-26 | 2004-01-07 | Novartis AG | Derivee de la pyridine |
JP2005504175A (ja) * | 2001-09-28 | 2005-02-10 | ダイムラークライスラー・アクチェンゲゼルシャフト | 高強度デュプレックス/トリプレックス軽量構造用鋼、及びその使用法 |
EP1461311A2 (fr) | 2001-12-26 | 2004-09-29 | Bayer HealthCare AG | Derives d'uree antagonistes du vr-1 |
EP1506166B1 (fr) | 2002-05-17 | 2011-11-16 | Janssen Pharmaceutica NV | Modulateurs de l'uree derives de l'aminotetraline du recepteur vanilloide vr1 |
AU2003238157A1 (en) | 2002-06-18 | 2003-12-31 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
WO2004028440A2 (fr) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Utilisation d'antagonistes du recepteur vanilloide pour le traitement de troubles urologiques |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
EP1553947A4 (fr) | 2002-10-21 | 2006-11-29 | Bristol Myers Squibb Co | Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa |
EP1608317B1 (fr) * | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidyle peptidase |
GB0326633D0 (en) | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
WO2005049613A1 (fr) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Pyrimidine-4-(3h)-ones bicycliques, leurs analogues et derives modulant la fonction du recepteur de vanilloide-1 (vr1) |
US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
AU2006244027A1 (en) * | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1) |
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
CN1318429C (zh) * | 2005-07-25 | 2007-05-30 | 华中师范大学 | 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶-4(3H)-酮及制备 |
WO2007056124A2 (fr) | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Composés destinés à moduler la fonction de trpv3 |
AU2007288203B2 (en) | 2006-08-23 | 2013-01-17 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
CN101563349A (zh) * | 2006-08-23 | 2009-10-21 | 神经能质公司 | 经卤烷基取代的嘧啶酮衍生物 |
EP2094704A4 (fr) * | 2006-11-06 | 2010-12-08 | Neurogen Corp | Dérivés de pyrimidinone substitués par cis-cyclohexyle |
WO2008156607A1 (fr) | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Pyrimidinones substituées |
WO2009100403A1 (fr) | 2008-02-07 | 2009-08-13 | Neurogen Corporation | Aryl pyrimidinones substitués |
WO2009121036A2 (fr) | 2008-03-27 | 2009-10-01 | Neurogen Corporation | Dérivés d'arylpyrimidone substitués |
-
2007
- 2007-08-22 AU AU2007288203A patent/AU2007288203B2/en not_active Ceased
- 2007-08-22 MX MX2009002066A patent/MX2009002066A/es unknown
- 2007-08-22 TW TW096131019A patent/TW200825089A/zh unknown
- 2007-08-22 KR KR1020097005810A patent/KR20090043583A/ko not_active Application Discontinuation
- 2007-08-22 CA CA2660957A patent/CA2660957C/fr not_active Expired - Fee Related
- 2007-08-22 CN CNA2007800309530A patent/CN101506210A/zh active Pending
- 2007-08-22 BR BRPI0716582-0A2A patent/BRPI0716582A2/pt not_active IP Right Cessation
- 2007-08-22 CN CN201410468406.2A patent/CN104292229A/zh active Pending
- 2007-08-22 EA EA200900330A patent/EA200900330A1/ru unknown
- 2007-08-22 ZA ZA200901163A patent/ZA200901163B/xx unknown
- 2007-08-22 ES ES07811503T patent/ES2399928T3/es active Active
- 2007-08-22 JP JP2009525630A patent/JP5421108B2/ja not_active Expired - Fee Related
- 2007-08-22 US US11/895,286 patent/US8003656B2/en active Active
- 2007-08-22 EP EP07811503A patent/EP2061794B1/fr active Active
- 2007-08-22 WO PCT/US2007/018654 patent/WO2008024438A2/fr active Application Filing
-
2009
- 2009-02-15 IL IL197043A patent/IL197043A0/en unknown
- 2009-02-20 NI NI200900023A patent/NI200900023A/es unknown
- 2009-02-20 SV SV2009003173A patent/SV2009003173A/es not_active Application Discontinuation
- 2009-02-23 GT GT200900040A patent/GT200900040A/es unknown
- 2009-03-18 CO CO09028167A patent/CO6150167A2/es unknown
- 2009-03-20 NO NO20091182A patent/NO20091182L/no not_active Application Discontinuation
- 2009-03-20 CR CR10675A patent/CR10675A/es not_active Application Discontinuation
- 2009-03-23 MA MA31732A patent/MA30720B1/fr unknown
-
2011
- 2011-08-22 US US13/215,195 patent/US8759361B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2007288203A1 (en) | 2008-02-28 |
EP2061794B1 (fr) | 2012-12-05 |
KR20090043583A (ko) | 2009-05-06 |
JP5421108B2 (ja) | 2014-02-19 |
NI200900023A (es) | 2010-03-05 |
EP2061794A2 (fr) | 2009-05-27 |
CO6150167A2 (es) | 2010-04-20 |
IL197043A0 (en) | 2009-11-18 |
US8759361B2 (en) | 2014-06-24 |
CA2660957A1 (fr) | 2008-02-28 |
BRPI0716582A2 (pt) | 2013-10-08 |
US20090069347A1 (en) | 2009-03-12 |
WO2008024438A3 (fr) | 2008-11-27 |
GT200900040A (es) | 2010-03-16 |
US20120208829A1 (en) | 2012-08-16 |
ZA200901163B (en) | 2010-08-25 |
ES2399928T3 (es) | 2013-04-04 |
AU2007288203B2 (en) | 2013-01-17 |
US8003656B2 (en) | 2011-08-23 |
CA2660957C (fr) | 2016-10-11 |
EA200900330A1 (ru) | 2009-08-28 |
SV2009003173A (es) | 2010-08-10 |
MX2009002066A (es) | 2009-03-06 |
CN101506210A (zh) | 2009-08-12 |
CR10675A (es) | 2009-04-17 |
NO20091182L (no) | 2009-05-14 |
JP2010502576A (ja) | 2010-01-28 |
TW200825089A (en) | 2008-06-16 |
CN104292229A (zh) | 2015-01-21 |
EP2061794A4 (fr) | 2010-09-08 |
WO2008024438A2 (fr) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30720B1 (fr) | Analogues de 2-phenoxypyrimidinone | |
WO2006049941A3 (fr) | Diaryl urees, antagonistes du cb1 | |
TW200605889A (en) | Substituted biaryl piperazinyl-pyridine analogues | |
MXPA05006123A (es) | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. | |
MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
MA28660B1 (fr) | Composes et compositions en tant que modulateurs de ppar | |
MA34474B1 (fr) | Agonistes de gpr40 | |
TW200716594A (en) | Substituted heteroaryl CB1 antagonists | |
WO2007101007A8 (fr) | Heterocycles sulfonyl aryliques | |
WO2007140383A3 (fr) | Sulfonamides spirocycliques et composés apparentés | |
TW200510373A (en) | Substituted quinolin-4-ylamine analogues | |
WO2006081388A3 (fr) | Analogues de pyridazinyl-et de pyrimidinyl-quinolin-4-ylamine substitues | |
WO2007146761A3 (fr) | Diaryl pyrimidinones et composés associés | |
WO2006078992A3 (fr) | Analogues de piperazinyl-pyridine à substitution hétéroaryle | |
WO2008016811A3 (fr) | Aminopipéridines et composés apparentés | |
WO2006042289A3 (fr) | Analogues de biaryl quinoline-4-ylamine a substitution | |
MA29723B1 (fr) | Composes | |
MA33299B1 (fr) | Nouvelle formulation de naproxène | |
WO2006089076A3 (fr) | Thiazole amides, imidazole amides et analogues associes | |
MA32798B1 (fr) | Acides naphtylacétiques | |
WO2005084401A3 (fr) | Analogues des purines à substitution aryle | |
WO2005023807A3 (fr) | Derives de quinazolin-4-ylamine bicyclique substitue | |
WO2008024433A3 (fr) | Dérivés de la pyrimidinone substitués par un halogénoalkyle | |
WO2008033739A3 (fr) | Dérivés de benzimidazolecarboxamide | |
MA31857B1 (fr) | N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci |